# A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.

> **NCT06766552** · — · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 10000 (estimated)

## Conditions studied

- Ankylosing Spondylitis (AS)
- Psoriatic Arthritis (PsA)
- Nr-axSpA
- Polymyalgia Rheumatica (PMR)
- Takayasu Arteritis (TAK)
- Giant Cell Arteritis (GCA)
- Behcet's Disease
- Enthesitis-related Arthritis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06766552
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-30
- **Primary completion:** 2029-12-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 10000 (ESTIMATED)
- **Last updated:** 2025-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06766552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06766552, "A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06766552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*